J.P. Morgan Healthcare Conference David J. Endicott Chief Executive Officer January 13th, 2026 Safe harbor Forward-looking statements This document contains, and our officers and representatives may from time to time make, certain "forward-looking statements" within the meaning of the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "anticipate," "intend," "commitment," "look forward," "maintain," "plan," "goal," ...

Core Insights - Alcon's Vision Care business is experiencing growth due to a diverse portfolio of contact lenses and ocular health products, with new product introductions expected to drive further growth in upcoming quarters [1][3][5] - The company has a market capitalization of $43.49 billion and has surpassed earnings estimates in three of the last four quarters, with an average surprise of 2.8% [2] - Despite a 6.7% stock rally over the past six months, Alcon faces challenges from adverse macroeconomic conditions and intense competition in the ophthalmology industry [1][8] Vision Care Growth - Alcon's Vision Care segment reported a 3% year-over-year sales increase in Q1 2025, driven by a 4% rise in contact lens sales due to product innovation and price increases [3][7] - The company is focusing on fast-growing market segments and has seen share gains from innovations like the PRECISION1 and TOTAL30 contact lens families [3] - Ocular health products, particularly the SYSTANE family of artificial tears, also contributed to growth with a 2% increase in sales year-over-year [3] New Product Launches - Alcon's R&D spending increased by 11.6% year-over-year in Q1 2025, supporting its innovation strategy [4] - New product launches include SYSTANE PRO Preservative-Free eye drops and Voyager DSLT for glaucoma treatment, with plans for broader rollouts in the future [5][7] Macroeconomic Challenges - Alcon's operations are impacted by macroeconomic pressures, including ongoing conflicts and unpredictable political conditions, particularly in emerging markets [6][8] - The company anticipates an $80 million increase in costs due to current tariffs affecting sales [6] Competitive Landscape - The ophthalmology industry is highly competitive, with Alcon facing challenges from both large and small manufacturers, as well as alternative therapies from pharmaceutical companies [8] - If Alcon fails to keep pace with innovation, its market position may be adversely affected [8] Financial Estimates - The Zacks Consensus Estimate for Alcon's 2025 earnings per share has decreased by 1% to $3.11, while revenue estimates are projected at $10.44 billion, indicating a 6.1% increase from the previous year [9]